Comparative study for the association of mitochondrial haplogroup F+ and metabolic syndrome between longevity and control population in Guangxi Zhuang Autonomous Region, China

• Published in: The Journal of nutrition, health & aging Vol. 22; no. 2; pp. 302 - 307
• Main Authors: Hu, C., He, X., Li, X., Sun, L., Zheng, C., Liang, Q., Lv, Z., Huang, Z., Qi, K., Yuan, H., Zhu, X., Yang, Y., Zhou, Q., Yang, Ze
• Format: Journal Article
• Language: English
• Published: Paris Springer Paris 01.02.2018; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Aging; Association; China; Comparative studies; Cross-Sectional Studies; DNA, Mitochondrial - genetics; Female; Geriatrics/Gerontology; Humans; Longevity; Male; Medicine; Medicine & Public Health; Metabolic syndrome; Metabolic Syndrome - genetics; Middle Aged; Mitochondrial DNA; Neurosciences; Nutrition; Primary Care Medicine; Quality of Life Research; China; mtDNA haplogroup F; longevity; Metabolic syndrome; Guangxi Zhuang autonomous region
• ISSN: 1279-7707; 1760-4788
• DOI: 10.1007/s12603-017-0915-2

Background Our previous study suggested that mitochondrial haplogroup F (mtDNA F) was a longevity-associated biomarker, but the effect of mitochondrial haplogroup F on longevity individuals with metabolic syndrome (MetS) was not clear. Thus we explored the association between mtDNA F and MetS among longevity and control population in Guangxi Zhuang Autonomous Region, China. Method A total of 793 individuals consisting of 307 long-lived participants and 486 local healthy controls were involved in this study. Genotypes of mtDNA F were amplified by polymerase chain reaction and Sanger sequenced. MetS was defined according to the revised National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATPIII ) criteria. Results The prevalence of MetS in longevity group (28.0%) was higher than that (18.5%) in control group (P=0.002). Through the case-control stratify analysis, the prevalence of MetS in mtDNA F+ longevity individuals (29.8%) was 4.6 fold higher than that (5.3%) in local control group (P<0.001). However, after further longevity-only analysis, no association between MetS and mtDNA F+ in longevity group was observed (P=0.167). Following same analysis of two variables in control group, we found that the prevalence of MetS in mtDNA F- (95.8%) was higher than that in mtDNA F+ (5.3%); conversely, the prevalence of non-metabolic syndrome (NMetS) in mtDNA F+ (94.7%) was markedly higher than that in mtDNA F- (4.2%) (P<0.001). Conclusion We demonstrated that mtDNA F+, as a molecuar biomarker, might not only confer beneficial effect to resistance against MetS but also function as a positive factor for long-life span among the population in Guangxi Zhuang Autonomous Region, China.